Sucharita Mistry, PhD

Cemiplimab monotherapy improved OS and PFS compared with chemotherapy in patients with advanced NSCLC with PD-L1 of at least 50%.

Overall survival was similar with pembrolizumab and single-agent chemotherapy.

The study showed differences in receipt of chemotherapy and surgery but not radiotherapy.

Quality of life outcomes were generally the same from baseline through follow-up.

A chemoimmunotherapy regimen with only 3 cycles of chemotherapy was found to be efficacious in a phase 2 trial that sought to reduce treatment-related MDS/AML in patients with CLL.

The results point to patients who might benefit from early intervention.

The response rate was higher for patients with pancreatic NETs than for those with gastrointestinal NETs.

Adding isatuximab to carfilzomib and dexamethasone improved outcomes.

A progression-free survival benefit did not translate to overall survival.

Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.